779 results on '"nonalcoholic steatohepatitis (NASH)"'
Search Results
152. Boehringer bets $2B in biobucks to unlock siRNA targets for MASH treatments.
- Author
-
Taylor, Nick Paul
- Subjects
SMALL interfering RNA ,LIFE sciences ,NON-alcoholic fatty liver disease - Abstract
Boehringer committed more than $2 billion in biobucks to enter into a multi-target pact with a Chinese biotech and its Swedish subsidiary. [ABSTRACT FROM AUTHOR]
- Published
- 2024
153. Gannex posts midphase data on NASH asset at center of trade secret row.
- Author
-
Taylor, Nick Paul
- Subjects
TRADE secrets ,NON-alcoholic fatty liver disease - Abstract
Gannex Pharma has [ABSTRACT FROM AUTHOR]
- Published
- 2024
154. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
- Author
-
Takatani, Naoki, Kono, Yuka, Beppu, Fumiaki, Okamatsu-Ogura, Yuko, Yamano, Yumiko, Miyashita, Kazuo, and Hosokawa, Masashi
- Subjects
- *
OXIDATIVE stress , *HIGH-fat diet , *FIBROSIS , *FATTY liver , *HEPATITIS , *XANTHOPHYLLS - Abstract
Nonalcoholic steatohepatitis (NASH) is associated with hepatocyte injury, excessive oxidative stress, and chronic inflammation in fatty liver, and can progress to more severe liver diseases, such as cirrhosis and hepatocellular carcinoma. However, currently there are no effective therapies for NASH. Marine carotenoid, fucoxanthin (Fx), abundant in brown seaweeds, has variable biological properties, such as anti-cancer, anti-inflammatory, anti-oxidative and anti-obesity. However, the effect of Fx on the development of NASH has not been explored. We investigated the protective effects of Fx in diet-induced NASH model mice fed choline-deficient L-amino acid-defined high fat diet (CDAHFD). Fx administration significantly attenuated liver weight gain and hepatic fat accumulation, resulting in the alleviation of hepatic injury. Furthermore, the Fx-fed mice, not only exhibited reduced hepatic lipid oxidation, but also decreased mRNA expression levels of inflammation and infiltration-related genes compared to that of the CDAHFD-fed mice. Moreover, fucoxanthinol and amarouciaxanthin A, two Fx metabolites exerted anti-inflammatory effects in the liver via inhibiting the chemokine production in hepatocytes. In case of fibrosis, one of the features of advanced NASH, the expression of fibrogenic factors including activated-hepatic stellate cell marker was significantly decreased in the liver of Fx-fed mice. Thus, the present study elucidated that dietary Fx not only inhibited hepatic oxidative stress and inflammation but also prevented early phase of fibrosis in the diet-induced NASH model mice. • Fucoxanthin significantly attenuates liver weight gain and hepatic fat accumulation. • Fucoxanthin suppresses lipid oxidation, and inflammation and infiltration genes. • Fucoxanthinol and amarouciaxanthin A, exert anti-inflammatory effects in liver. • Fucoxanthin prevents early phase of fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
155. 肝移植治疗非酒精性脂肪性肝病的研究现状.
- Author
-
杨洲 and 傅斌生
- Abstract
Liver transplantation is the most effective means to treat the related end-stage liver disease caused by non-alcoholic fatty liver disease (NAFLD). But the recurrence rate of NAFLD after liver transplantation is very high due to the affection of obesity, metabolic syndrome and other adverse factors. In recent years, liver transplantation for NAFLD related end-stage liver disease has made some progress both in China and abroad. This article reviews the research progress of NAFLD and liver transplantation for NAFLD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
156. 逍遥散对非酒精性脂肪性肝炎大鼠Toll样受体4 基因甲基化水平的调节作用.
- Author
-
徐慧超, 高艳, 陈浩, 郝健亨, 刘晋芳, 刘杨, and 苗宇船
- Abstract
Objective To explore the new mechanism of changes in TLR4 gene methylation levels in the treatment of liver stagnation and spleen deficiency pattern in non-alcoholic steatohepatitis (NASH) in rats with Xiaoyao San (Xiaoyao Powder). Methods 30 male SD rats were randomly divided into blank group,model group and Xiaoyao San group (n = 10). Rats in the blank group were given normal diet for 28 weeks, followed by injection of normal saline for 4 weeks. In the model group and Xiaoyao San group, liver stagnation and spleen deficiency pattern model was established by feeding the rate with a high-fat and high-sugar diet with stimulations of chronic stress and irregular diets for 28 weeks In the last 4 weeks, the model group and Xiaoyao San group were injected with normal saline and Xiaoyao San solution respectively. At the end of 28 weeks, urine was collected from the three groups,and the liver and hippocampus tissues were taken to make pathological sections. The corresponding indicators were detected by real-time fluorescence quantitative PCR (qPCR),enzyme-linked immunosorbent assay (ELISA),and hydrogen sulfite sequencing PCR (BSP),etc. Results Compared with the model group,the symptoms of liver stagnation and spleen deficiency pattern were significantly alleviated with a decreased pattern score in the Xiaoyao San group. The numbers of fat vacuoles and infiltration degree of inflammatory cells in liver cells were significantly reduced. The TLR4 mRNA content in liver tissues was decreased? while the methylation level of TLR4 gene was increased (P < 0. 05). Conclusion Xiaoyao San may up-regulate the TLR4 gene methylation level and down-regulate the TLR4 mRNA expression in rats with liver stagnation and spleen deficiency pattern in non-alcoholic steatohepatitis, thus improving the degree of liver steatosis and alleviating inflammation and other symptoms. This seems to be the new mechanism for the treatment of such condition with Xiaoyao San. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
157. Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.
- Author
-
Chen, Ming-Ming, Cai, Jing-Jing, Yu, Yao, She, Zhi-Gang, and Li, Hongliang
- Subjects
FATTY liver ,BARIATRIC surgery ,LIVER transplantation ,OXIDATIVE stress ,CLINICAL trials - Abstract
Nonalcoholic steatohepatitis (NASH) is the second leading cause of liver transplantation in the US with a high risk of liver-related morbidities and mortality. Given the global burden of NASH, development of appropriate therapeutic strategies is an important clinical need. Where applicable, lifestyle modification remains the primary recommendation for the treatment of NASH, even though such changes are difficult to sustain and even insufficient to cure NASH. Bariatric surgery resolves NASH in such patients where lifestyle modifications have failed, and is recommended for morbidly obese patients with NASH. Thus, pharmacotherapies are of high value for NASH treatment. Though no drug has been approved by the US Food and Drug Administration for treatment of NASH, substantial progress in pharmacological development has been made in the last few years. Agents such as vitamin E and pioglitazone are recommended in patients with NASH, and yet concerns about their side effects remain. Many agents targeting various vital molecules and pathways, including those impacting metabolic perturbations, inflammatory cascades, and oxidative stress, are in clinical trials for the treatment of NASH. Some agents have shown promising results in phase II or III clinical trials, but more studies are required to assess their long-term effects. Herein, we review the potential strategies and challenges in therapeutic approaches to treating NASH. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
158. Nonalcoholic Fatty Liver Disease
- Author
-
Smolle, Elisabeth, Kessler, Sonja M., Golob, Nicole, Haybaeck, Johannes, and Ahima, Rexford S., editor
- Published
- 2016
- Full Text
- View/download PDF
159. Hepatobiliary and Pancreatic Interventions
- Author
-
Gopee-Ramanan, Prasaanthan and Athreya, Sriharsha, editor
- Published
- 2016
- Full Text
- View/download PDF
160. Nonalcoholic Fatty Liver Disease Post-Liver Transplantation
- Author
-
Hanouneh, Ibrahim, Eghtesad, Bijan, and Thuluvath, Paul J., editor
- Published
- 2016
- Full Text
- View/download PDF
161. Baseline Presence of NAFLD Predicts Weight Loss after Gastric Bypass Surgery for Morbid Obesity.
- Author
-
RHEINWALT, KARL PETER, DREBBER, UTA, SCHIERWAGEN, ROBERT, KLEIN, SABINE, NEUMANN, ULF PETER, ULMER, TOM FLORIAN, PLAMPER, ANDREAS, KROH, ANDREAS, SCHIPPER, SANDRA, ODENTHAL, MARGARETE, USCHNER, FRANK ERHARD, LINGOHR, PHILIPP, TREBICKA, JONEL, and BROL, MAXIMILIAN JOSEPH
- Subjects
- *
GASTRIC bypass , *WEIGHT loss , *MORBID obesity , *BARIATRIC surgery , *NON-alcoholic fatty liver disease , *BODY mass index - Abstract
Background: Bariatric surgery is a widely used treatment for morbid obesity. Prediction of postoperative weight loss currently relies on prediction models, which mostly overestimate patients' weight loss. Data about the influence of nonalcoholic fatty liver disease (NAFLD) on early postoperative weight loss are scarce. Methods: This prospective, single-center cohort study included 143 patients receiving laparoscopic gastric bypass surgery (one anastomosis-mini gastric bypass [OAGB-MGB] or Roux-en-Y gastric bypass [RYGB]). Liver biopsies were acquired at surgery. NAFLD activity score (NAS) assigned patients to "No NAFLD," "NAFL," or "NASH." Follow-up data were collected at 3, 6, and 12 months. Results: In total, 49.7 percent of patients had NASH, while 41.3 percent had NAFL. Compared to the No NAFLD group, NAFL and NASH showed higher body mass index (BMI) at follow-up (6 months: 31.0kg/m2 vs. 36.8kg/m2 and 36.1kg/m2, 12 months: 27.0kg/m2 vs. 34.4 and 32.8kg/m2) and lower percentage of total body weight loss (%TBWL): (6 months: 27.1% vs. 23.3% and 24.4%; 12 months: 38.5% vs. 30.1 and 32.6%). Linear regression of NAS points significantly predicts percentage of excessive weight loss (%EWL) after 6 months (Cologne-weight-loss-prediction-score). Conclusion: Histopathological presence of NAFLD might lead to inferior postoperative weight reduction after RYGB. The mechanisms underlying this observation should be further studied. [ABSTRACT FROM AUTHOR]
- Published
- 2021
162. Cholesterol Absorption Inhibitor Ezetimibe: Risk–Benefits and Role in Treating Dyslipidemias
- Author
-
Yamashita, Shizuya, Masuda, Daisaku, Matsuyama, Akifumi, Conn, P. Michael, Series editor, and Garg, Abhimanyu, editor
- Published
- 2015
- Full Text
- View/download PDF
163. Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
- Author
-
Scott Cotler, MD, Professor of Medicine
- Published
- 2013
164. Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid
- Author
-
Nanlin Zhu, Suling Huang, Qingli Zhang, Zhuohui Zhao, Hui Qu, Mengmeng Ning, Ying Leng, and Jia Liu
- Subjects
nonalcoholic fatty liver disease (NAFLD) ,nonalcoholic fatty liver (NAFL) ,nonalcoholic steatohepatitis (NASH) ,differential metabolites ,metabolic pathways ,obeticholic acid (OCA) ,Microbiology ,QR1-502 - Abstract
The pathophysiology of nonalcoholic fatty liver disease (NAFLD) is a complex process involving metabolic and inflammatory changes in livers and other organs, but the pathogenesis is still not well clarified. Two mouse models were established to study metabolic alteration of nonalcoholic fatty liver and nonalcoholic steatohepatitis, respectively. The concentrations of metabolites in serum, liver and intestine content were measured by the AbsoluteIDQ® p180 Kit (Biocrates Life Sciences, Innsbruck, Austria). Multivariate statistical methods, pathway analysis, enrichment analysis and correlation analysis were performed to analyze metabolomic data. The metabolic characteristics of liver, serum and intestine content could be distinctly distinguished from each group, indicating the occurrence of metabolic disturbance. Among them, metabolic alteration of liver and intestine content was more significant. Based on the metabolic data of liver, 19 differential metabolites were discovered between DIO and control, 12 between DIO-CCl4 and DIO, and 47 between DIO-CCl4 and normal. These metabolites were mainly associated with aminoacyl-tRNA biosynthesis, nitrogen metabolism, lipid metabolism, glyoxylate and dicarboxylate metabolism, and amino metabolism. Further study revealed that the intervention of obeticholic acid (OCA) could partly reverse the damage of CCl4. The correlation analysis of metabolite levels and clinical parameters showed that phosphatidylcholines were negatively associated with serum alanine aminotransferase, aspartate aminotransferase, NAFLD activity score, and fibrosis score, while lysophosphatidylcholines, sphingomyelins, amino acids, and acylcarnitines shared the reverse pattern. Our study investigated metabolic alteration among control, NAFLD model, and OCA treatment groups, providing preclinical information to understand the mechanism of NAFLD and amelioration of OCA.
- Published
- 2021
- Full Text
- View/download PDF
165. Cisd2 Protects the Liver from Oxidative Stress and Ameliorates Western Diet-Induced Nonalcoholic Fatty Liver Disease
- Author
-
Yi-Long Huang, Zhao-Qing Shen, Chen-Hua Huang, Yuan-Chi Teng, Chao-Hsiung Lin, and Ting-Fen Tsai
- Subjects
nonalcoholic fatty liver disease (NAFLD) ,nonalcoholic steatohepatitis (NASH) ,Cisd2 ,Western diet ,transcriptomics ,hepatocyte-specific knockout ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), are the most common chronic liver diseases worldwide. However, drugs to treat NAFLD and NASH are an unmet clinical need. This study sought to provide evidence that Cisd2 is a molecular target for the development of treatments targeting NAFLD and NASH. Several discoveries are pinpointed. The first is that Cisd2 dosage modulates the severity of Western diet-induced (WD-induced) NAFLD. Specifically, Cisd2 haploinsufficiency accelerates NAFLD development and exacerbates progression toward NASH. Conversely, an enhanced Cisd2 copy number attenuates liver pathogenesis. Secondly, when a WD is fed to mice, transcriptomic analysis reveals that the major alterations affecting biological processes are related to inflammation, lipid metabolism, and DNA replication/repair. Thirdly, among these differentially expressed genes, the most significant changes involve Nrf2-mediated oxidative stress, cholesterol biosynthesis, and fatty acid metabolism. Finally, increased Cisd2 expression protects the liver from oxidative stress and reduces the occurrence of mitochondrial DNA deletions. Taken together, our mouse model reveals that Cisd2 plays a crucial role in protecting the liver from WD-induced damages. The development of therapeutic agents that effectively enhance Cisd2 expression is one potential approach to the treatment of WD-induced fatty liver diseases.
- Published
- 2021
- Full Text
- View/download PDF
166. Verification of B-lymphocyte activating factor’s involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease
- Author
-
Takashi Himoto, Koji Fujita, Takako Nomura, Joji Tani, Asahiro Morishita, Hirohito Yoneyama, Reiji Haba, and Tsutomu Masaki
- Subjects
Antinuclear antibody (ANA) ,B-lymphocyte activating factor (BAFF) ,Hepatitis C virus (HCV) ,Insulin resistance ,Nonalcoholic steatohepatitis (NASH) ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Ten to forty percent of nonalcoholic steatohepatitis (NASH) and HCV-related chronic liver disease (CLD-C) patients have antinuclear antibodies (ANAs). However, the relationship between autoimmune response and insulin resistance remains uncertain among those patients. The primary purpose of this study was to investigate whether or not ANA status was associated with the development of insulin resistance and obesity in NASH and CLD-C patients. Methods Degrees of hepatic fibrosis and steatosis were evaluated by the classification proposed by Brunt et al. Obesity and insulin resistance were estimated by calculating body mass index and the value of homeostasis model of for assessment of insulin resistance (HOMA-IR), respectively. A revised scoring system was applied to the diagnosis of autoimmune hepatitis (AIH). Serum B-lymphocyte activating factor (BAFF) levels were determined, using an ELISA technique. Results Ten of 25 (40%) NASH patients and 9 of 22 (41%) CLD-C patients had ANAs, though the titers were weak in most patients. Only one NASH patient met the category of “definite” AIH among the enrolled patients. Serum IgG levels were significantly higher in NASH and CLD-C patients with ANAs than in those without ANAs, and NASH and CLD-C patients with ANAs had significantly higher HOMA-IR values than those without ANAs (6.81 ± 3.36 vs. 4.00 ± 2.57, p = 0.0305, 3.01 ± 1.31 vs. 1.28 ± 0.50, p = 0.0011). CLD-C patients with ANAs had more advanced hepatic fibrosis and steatosis than those without ANAs, while ANA status was not associated with hepatic fibrosis or steatosis in NASH patients. Obesity was independent of ANA status in both subjects. Serum BAFF levels were significantly higher in CLD-C patients with ANAs than those in CLD-C patients without ANAs (1303 ± 268 vs. 714 ± 143 pg/ml, p = 0.0036). A close correlation between serum BAFF level and the HOMA-IR value was observed in CLD-C patients (r = 0.467, p = 0.0485). Conclusion Our data suggest that NASH and CLD-C patients with ANAs have more severe insulin resistance than those without ANAs. More advanced insulin resistance deriving from excessive BAFF production may result in severe hepatic fibrosis and steatosis in CLD-C patients with ANAs.
- Published
- 2017
- Full Text
- View/download PDF
167. Antiretroviral Therapies for Human Immunodeficiency Virus and Liver Disease: Challenges and opportunities
- Author
-
Julio C. Abarca, Leonor Huerta, and Nora A. Fierro
- Subjects
Liver fibrosis ,Nucleoside reverse transcriptase inhibitors (NRTIs) ,Protease inhibitors (PIs) ,Nonalcoholic fatty liver disease (NAFLD) ,Nonalcoholic steatohepatitis (NASH) ,Coinfections ,Specialties of internal medicine ,RC581-951 - Abstract
Summary: The post antiretroviral therapy (ART) era for human immunodeficiency virus (HIV) infection resulted in a dramatically increased proportion of deaths attributed to liver-related causes in patients with HIV treated with ART. Additionally, as patients become older as a result of effective ART, liver-related conditions and application of safe therapies are now major concerns in the setting of HIV infection.
- Published
- 2020
- Full Text
- View/download PDF
168. Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease
- Published
- 2012
169. Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD)
- Author
-
Xin Xin, Cheng Chen, Yi-Yang Hu, and Qin Feng
- Subjects
Genistein ,Soy ,Nonalcoholic steatohepatitis (NASH) ,Non-alcoholic fatty liver disease (NAFLD) ,Review ,Therapeutics. Pharmacology ,RM1-950 - Abstract
NAFLD is a vital health problem worldwide; however, no effective treatment is currently available for NAFLD. Intensive studies have indicated the efficacy of genistein (GE), a bioactive isoflavone extracted from soy, in treating NAFLD. In addition to its oestrogen-like effects, GE is known to have multiple molecular effects, for instance, lipid and glucose metabolism-promoting effects and activities against lipid peroxidation, inflammation, fibrosis, and NAFLD-related tumours. Here, this review summarizes the potential role of GE in the treatment and prevention of NAFLD and some of the currently known targets and signalling pathways of GE in NAFLD.
- Published
- 2019
- Full Text
- View/download PDF
170. Up-to-date global epidemiology of nonalcoholic fatty liver disease.
- Author
-
Manikat R, Ahmed A, and Kim D
- Abstract
Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-548/coif). The authors have no conflicts of interest to declare.
- Published
- 2023
- Full Text
- View/download PDF
171. Higher consumption of animal organ meat is associated with a lower prevalence of nonalcoholic steatohepatitis.
- Author
-
Zhang R, Zhang H, Wang Y, Tang LJ, Li G, Huang OY, Chen SD, Targher G, Byrne CD, Gu BB, and Zheng MH
- Abstract
Background: Animal organ meat (offal) is a food with high nutrient density that is popular in different parts of the world, but its relationship with nonalcoholic steatohepatitis (NASH) is unclear. We aimed to examine whether daily animal organ meat consumption is associated with the presence of NASH in individuals with nonalcoholic fatty liver disease (NAFLD)., Methods: A total of 136 Chinese adults with biopsy-proven NAFLD were included. Definite NASH was defined as NAFLD activity score ≥4 and at least one point for steatosis, ballooning, and lobular inflammation. Daily animal organ meat consumption was estimated using a self-administered validated food frequency questionnaire. Logistic regression analysis was performed to assess the association between animal organ meat intake and liver disease severity., Results: The 136 participants (80.9% men) of the study had a mean ± standard deviation (SD) age of 39.0±12.5 years and body mass index of 27.4±3.6 kg/m
2 . Prevalence of definite NASH was 65.4%. Daily median organ meat consumption was 1.30 g/1,000 kcal. Animal organ meat consumption was inversely associated with the presence of NASH even after adjustment of demographics, lifestyle variables, metabolic and dietary factors, as well as liver fibrosis stage; adjusted-odds ratios (95% confidence intervals) for NASH were 0.15 (0.03, 0.69) for the highest tertile and 0.18 (0.05, 0.70) for the medium tertile, compared to the lowest (reference) tertile of animal organ meat intake (P value for trend =0.024)., Conclusions: Our results suggest for the first time that higher animal organ meat consumption is associated with a lower prevalence of NASH in Chinese individuals with biopsy-proven NAFLD., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-21-468/coif). MHZ serves as an unpaid editorial board member of Hepatobiliary Surgery and Nutrition. The other authors have no conflicts of interest to declare., (2023 Hepatobiliary Surgery and Nutrition. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
172. Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved.
- Author
-
Yoneda M, Kobayashi T, Wada N, Otani T, Nogami A, Iwaki M, and Nakajima A
- Abstract
Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-342/coif). The authors have no conflicts of interest to declare.
- Published
- 2023
- Full Text
- View/download PDF
173. Identification of Accessible Hepatic Gene Signatures for Interindividual Variations in Nutrigenomic Response to Dietary Supplementation of Omega-3 Fatty Acids
- Author
-
Yu Shi, Ping Li, Cheng-fei Jiang, Yi Chen, Yonghe Ma, Nikhil Gupta, Xiangbo Ruan, and Haiming Cao
- Subjects
omega-3 fatty acids ,cardiometabolic disease ,hyperlipidemia ,nonalcoholic fatty liver disease (NAFLD) ,nonalcoholic steatohepatitis (NASH) ,humanized mice ,Cytology ,QH573-671 - Abstract
Dietary supplementation is a widely adapted strategy to maintain nutritional balance for improving health and preventing chronic diseases. Conflicting results in studies of similar design, however, suggest that there is substantial heterogenicity in individuals’ responses to nutrients, and personalized nutrition is required to achieve the maximum benefit of dietary supplementation. In recent years, nutrigenomics studies have been increasingly utilized to characterize the detailed genomic response to a specific nutrient, but it remains a daunting task to define the signatures responsible for interindividual variations to dietary supplements for tissues with limited accessibility. In this work, we used the hepatic response to omega-3 fatty acids as an example to probe such signatures. Through comprehensive analysis of nutrigenomic response to eicosapentaneoid acid (EPA) and/or docosahexaenoic acid (DHA) including both protein coding and long noncoding RNA (lncRNA) genes in human hepatocytes, we defined the EPA- and/or DHA-specific signature genes in hepatocytes. By analyzing gene expression variations in livers of healthy and relevant disease populations, we identified a set of protein coding and lncRNA signature genes whose responses to omega-3 fatty acid exhibit very high interindividual variabilities. The large variabilities of individual responses to omega-3 fatty acids were further validated in human hepatocytes from ten different donors. Finally, we profiled RNAs in exosomes isolated from the circulation of a liver-specific humanized mouse model, in which the humanized liver is the sole source of human RNAs, and confirmed the in vivo detectability of some signature genes, supporting their potential as biomarkers for nutrient response. Taken together, we have developed an efficient and practical procedure to identify nutrient-responsive gene signatures as well as accessible biomarkers for interindividual variations.
- Published
- 2021
- Full Text
- View/download PDF
174. Noninvasive Differential Diagnosis of Liver Iron Contents in Nonalcoholic Steatohepatitis and Simple Steatosis Using Multiecho Dixon Magnetic Resonance Imaging.
- Author
-
Kim, Tae-Hoon, Jeong, Chang-Won, Jun, Hong Young, Kim, Youe Ree, Kim, Ju Young, Lee, Young Hwan, and Yoon, Kwon-Ha
- Abstract
Rationale and Objectives: The roles of iron stores in nonalcoholic fatty liver disease have not yet been clearly identified, and it is lack of uniform criteria and a standardized study design for assessing the liver iron content (LIC) in nonalcoholic steatohepatitis (NASH). This study was to compare LICs in biopsy-proven simple steatosis (SS) and NASH based on T2⁎-relaxometry.Material and Methods: A total of 32 subjects divided to three groups, consisting of 10 healthy controls, 12 SS and 10 NASH. All MRI examinations were performed on a 3 T MRI with a 32-channel body coil. To measure T2⁎-value, we used a gradient echo sequence with six multiechoes within a single breath-hold. Hepatic iron contents among three groups were compared using Kruskal-Wallis H test and Mann-Whitney's posthoc tests. Diagnostic accuracy was determined by calculating the area under the receiver operating characteristics curve. To identify the reliability of iron measurements in the different region of interests, coefficient of variance (CV) was calculated overall CV values for the variability of measurements. Interobserver agreement and reliability were estimated by calculating the intraclass correlation coefficient.Results: The variations of all LIC measurements are not exceeded 20%, as a mean CV value 18.3%. intraclass correlation coefficients were higher than 0.9. Mean T2⁎-values at localized region of interests were healthy controls 45.42 ± 7.19 ms, SS 20.96 ± 4.28 ms, and NASH 15.49 ± 2.87 ms. The mean T2⁎-value in NASH is significantly shorter than that in SS (p = 0.008). The area under the receiver operating characteristics curve to distinguish NASH from SS was 0.908 (95% confidence interval 0.775-1.000, p = 0.001) at a cut-off of iron contents greater than 17.95 ms, and its diagnostic accuracy had 0.833 sensitivity and 0.800 specificity.Conclusion: This study demonstrates that the T2⁎ calculation can help to differentially diagnose NASH. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
175. Endotoxin regulates matrix genes increasing reactive oxygen species generation by intercellular communication between palmitate‐treated hepatocyte and stellate cell.
- Author
-
Dornas, Waleska, Glaise, Denise, Bodin, Aude, Sharanek, Ahmad, Burban, Audrey, Le Guillou, Dounia, Robert, Sacha, Dutertre, Stephanie, Aninat, Caroline, Corlu, Anne, and Lagente, Vincent
- Subjects
- *
ENDOTOXINS , *REACTIVE oxygen species , *HEPATOCYTE growth factor , *KUPFFER cells , *MACROPHAGES - Abstract
Previous studies have shown that gut‐derived bacterial endotoxins contribute in the progression of simple steatosis to steatohepatitis, although the mechanism(s) remains inaccurate to date. As hepatic stellate cells (HSC) play a pivotal role in the accumulation of excessive extracellular matrix (ECM), leading to collagen deposition, fibrosis, and perpetuation of inflammatory response, an in vitro model was developed to investigate the crosstalk between HSC and hepatocytes (human hepatoma cell) pretreated with palmitate. Bacterial lipopolysaccharide (LPS) stimulated HSC with phosphorylation of the p38 mitogen‐activated protein kinase/NF‐κB pathway, while several important pro‐inflammatory cytokines were upregulated in the presence of hepatocyte–HSC. Concurrently, fibrosis‐related genes were regulated by palmitate and the inflammatory effect of endotoxin where cells were more exposed or sensitive to reactive oxygen species (ROS). This interaction was accompanied by increased expression of the mitochondrial master regulator, proliferator‐activated receptor gamma coactivator alpha, and a cytoprotective effect of the agent N‐acetylcysteine suppressing ROS production, transforming growth factor‐β1, and tissue inhibitor of metalloproteinase‐1. In summary, our results demonstrate that pro‐inflammatory mediators LPS‐induced promote ECM rearrangement in hepatic cells transcriptionally committed to the regulation of genes encoding enzymes for fatty acid metabolism in light of differences that might require an alternative therapeutic approach targeting ROS regulation. Hepatocyte–hepatic stellate cells (HSCs) crosstalk resulted in the overexpression of inflammatory genes when lipopolysaccharide (LPS)‐treated. Higher production of reactive oxygen species/proliferator‐activated receptor gamma coactivator alpha activation was found to LPS‐palmitate treatment in hepatocytes–HSCs. LPS‐palmitate induced a fibrogenic status in hepatocyte–HSCs related to oxidative stress, where tissue inhibitors of metalloproteinase 1 and transforming growth factor‐β1 were N‐acetylcysteine‐modulated. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
176. Growth Hormone Deficiency and Nonalcoholic Fatty Liver Disease with Insights from Humans and Animals: Pediatric Implications.
- Author
-
Henry, Rohan K.
- Abstract
In addition to its growth promoting role, growth hormone (GH) has a significant effect on intermediary metabolism in the well state. Despite the latter fact, pediatric practitioners are usually focused on the growth promoting aspects of GH as opposed to those metabolic. In recent years various animal and human studies (in adults mainly) and clinical reports in children have repeatedly shown the association of GH deficiency (GHD) and fatty liver disease. Based on this well-identified association, despite a lack of studies involving children, it behooves the pediatric clinician to ensure that not only patients with GHD are appropriately treated but also that adolescents even beyond the period of linear growth should be appropriately transitioned to adult GH therapy should this be appropriate. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
177. Pathogenesis of NASH: the Impact of Multiple Pathways.
- Author
-
Noureddin, Mazen and Sanyal, Arun J.
- Abstract
Purpose of review: Advancing our understanding of the mechanisms that underlie NASH pathogenesis.Recent findings: Recent findings on NASH pathogenesis have expanded our understanding of its complexity including (1) there are multiple parallel hits that lead to NASH; (2) the microbiota play an important role in pathogenesis, with bacterial species recently shown to accurately differentiate between NAFL and NASH patients; (3) the main drivers of liver cell injury are lipotoxicity caused by free fatty acids (FFAs) and their derivatives combined with mitochondrial dysfunction; (4) decreased endoplasmic reticulum (ER) efficiency with increased demand for protein synthesis/folding/repair results in ER stress, protracted unfolded protein response, and apoptosis; (5) upregulated proteins involved in multiple pathways including JNK, CHOP, PERK, BH3-only proteins, and caspases result in mitochondrial dysfunction and apoptosis; and (6) subtypes of NASH in which these pathophysiological pathways vary may require patient subtype identification to choose effective therapy.Summary: Recent pathogenesis studies may lead to important therapeutic advances, already seen in patients treated with ACC, ASK1 and SCD1 inhibitors, and FXR agonists. Further, advancing our understanding of mechanisms underlying NASH pathogenesis and the complex interplay between them will be crucial for developing effective therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
178. Protective Effects and Action Mechanism of Total Flavonoids of POLYGONI PERFOLIATI HERBA on Rats with Nonalcoholic Steatohepatitis.
- Author
-
Ya GAO, Kefeng ZHANG, and Riming WEI
- Subjects
- *
FATTY liver , *FLAVONOIDS , *LABORATORY rats , *BLOOD testing , *LOW density lipoproteins - Abstract
[Objectives] To study the protective effects and mechanism of POLYGONI PERFOLIATI HERBA on rats with nonalcoholic steatohepatitis (NASH). [Methods] Sixty rats were randomly divided into normal group, model group, metformin group (0.5 mg/kg), and high dose, medium dose, and low dose groups of total flavonoids of POLYGONI PERFOLIATI HERBA (600, 300, 150 mg kg). The standard feed was given to the normal group, and the model group and the total flavonoids groups were fed with high-fat diet for 13 weeks to establish the NASH rat model. At the 8th week, the metformin group and the POLYGONI PERFOLIATI HERBA total flavonoids groups were given with the corresponding drug treatment for 6 weeks, blood was taken from the eyeball to collect liver tissue. Biochemical method was used to determine ALT, AST, TC, TG, HDL-c, LDL-c, SOD, MDA, GSH-Px activity or content in serum and HOMA-IR, and ELISA was used to measure the TNF-oi, IL-1 $ and IL -6 content in liver tiisue; Western blotting was used to detect the expression levels of AMPK, p-AMPK and ACC in liver tiisue. [Results] Total flavonoids of POLYGONI PERFOLIATI HERBA could significantly decrease the activity or content of ALT, AST and MDA in serum of NASH rat (P < 0.05, P < 0.01), and enhance the activity of SOD and GSH-Px (P < 0.05, P < 0.01), reduce serumTC, TG, LDL-c levels and insulin resistance index, increase HDL-c levels (P < 0.05, P < 0.01); down-regulate liver IL-1β, IL-6, TNF-α, ACC levels and up-regulate p-AMPK expression (P < 0.05, P < 0.01). [Conclusions] The total flavonoids of POLYGONI PERFOLIATI HERBA have a good protective effect on NASH rats, and its mechanism may be related to the functons of regulating the lipid metabolism, aHeviating insulin resistance, inhibiting oxidative stress, inhibiting inflammatory reaction and regulating AMPK and ACC protein expression. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
179. Akero's NASH miss drags a few peers down, spurring deja vu in long-challenging indication.
- Author
-
Armstrong, Annalee
- Subjects
NON-alcoholic fatty liver disease ,PEERS - Abstract
Things were going pretty well in the NASH landscape, but yesterday the space came crashing back down to reality with the failure of Akero's med. [ABSTRACT FROM AUTHOR]
- Published
- 2023
180. Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
- Author
-
Alessandro Mantovani, Graziana Petracca, Alessandro Csermely, Giorgia Beatrice, and Giovanni Targher
- Subjects
SGLT-2 inhibitors ,type 2 diabetes mellitus ,nonalcoholic fatty liver disease ,NAFLD ,nonalcoholic steatohepatitis ,nonalcoholic steatohepatitis (NASH) ,Microbiology ,QR1-502 - Abstract
Recent randomized controlled trials (RCTs) tested the efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors to specifically treat nonalcoholic fatty liver disease (NAFLD). We systematically searched three electronic databases (up to 31 October 2020) for identifying placebo-controlled or head-to-head RCTs that used SGLT-2 inhibitors for treatment of NAFLD. No published RCTs with paired liver biopsy data were available for the meta-analysis. Primary outcome measures were changes in serum liver enzyme levels and liver fat content on imaging techniques. Overall, we included a total of twelve RCTs testing the efficacy of dapagliflozin (n = six RCTs), empagliflozin (n = three RCTs), ipragliflozin (n = two RCTs) or canagliflozin (n = one RCT) to specifically treat NAFLD for a median period of 24 weeks with aggregate data on 850 middle-aged overweight or obese individuals with NAFLD (90% with type 2 diabetes). Compared to placebo/reference therapy, treatment with SGLT-2 inhibitors significantly decreased serum alanine aminotransferase (weighted mean differences (WMD): −10.0 IU/L, 95%CI −12.2 to −7.79 IU/L; I2 = 10.5%) and gamma-glutamyltransferase levels (WMD: −14.49 IU/L, 95%CI −19.35 to −9.63 IU/L, I2 = 38.7%), as well as the absolute percentage of liver fat content on magnetic resonance-based techniques (WMD: −2.05%, 95%CI −2.61 to −1.48%; I2 = 0%). In conclusion, SGLT-2 inhibitors seem to be a promising treatment option for NAFLD.
- Published
- 2020
- Full Text
- View/download PDF
181. Comparative Transcriptomics Analyses in Livers of Mice, Humans, and Humanized Mice Define Human-Specific Gene Networks
- Author
-
Chengfei Jiang, Ping Li, Xiangbo Ruan, Yonghe Ma, Kenji Kawai, Hiroshi Suemizu, and Haiming Cao
- Subjects
nonalcoholic fatty liver disease (NAFLD) ,nonalcoholic steatohepatitis (NASH) ,humanized mice ,liver ,Cytology ,QH573-671 - Abstract
Mouse is the most widely used animal model in biomedical research, but it remains unknown what causes the large number of differentially regulated genes between human and mouse livers identified in recent years. In this report, we aim to determine whether these divergent gene regulations are primarily caused by environmental factors or some of them are the result of cell-autonomous differences in gene regulation in human and mouse liver cells. The latter scenario would suggest that many human genes are subject to human-specific regulation and can only be adequately studied in a human or humanized system. To understand the similarity and divergence of gene regulation between human and mouse livers, we performed stepwise comparative analyses in human, mouse, and humanized livers with increased stringency to gradually remove the impact of factors external to liver cells, and used bioinformatics approaches to retrieve gene networks to ascertain the regulated biological processes. We first compared liver gene regulation by fatty liver disease in human and mouse under the condition where the impact of genetic and gender biases was minimized, and identified over 50% of all commonly regulated genes, that exhibit opposite regulation by fatty liver disease in human and mouse. We subsequently performed more stringent comparisons when a single specific transcriptional or post-transcriptional event was modulated in vitro or vivo or in liver-specific humanized mice in which human and mouse hepatocytes colocalize and share a common circulation. Intriguingly and strikingly, the pattern of a high percentage of oppositely regulated genes persists under well-matched conditions, even in the liver of the humanized mouse model, which represents the most closely matched in vivo condition for human and mouse liver cells that is experimentally achievable. Gene network analyses further corroborated the results of oppositely regulated genes and revealed substantial differences in regulated biological processes in human and mouse cells. We also identified a list of regulated lncRNAs that exhibit very limited conservation and could contribute to these differential gene regulations. Our data support that cell-autonomous differences in gene regulation might contribute substantially to the divergent gene regulation between human and mouse livers and there are a significant number of biological processes that are subject to human-specific regulation and need to be carefully considered in the process of mouse to human translation.
- Published
- 2020
- Full Text
- View/download PDF
182. DNA Methylation in Nonalcoholic Fatty Liver Disease
- Author
-
Jeongeun Hyun and Youngmi Jung
- Subjects
nonalcoholic fatty liver disease (NAFLD) ,nonalcoholic steatohepatitis (NASH) ,DNA methylation ,epigenetics ,cytosine-phospho-guanine dinucleotide (CpG) ,biomarker ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Nonalcoholic fatty liver disease (NAFLD) is a widespread hepatic disorder in the United States and other Westernized countries. Nonalcoholic steatohepatitis (NASH), an advanced stage of NAFLD, can progress to end-stage liver disease, including cirrhosis and liver cancer. Poor understanding of mechanisms underlying NAFLD progression from simple steatosis to NASH has limited the development of effective therapies and biomarkers. An accumulating body of studies has suggested the importance of DNA methylation, which plays pivotal roles in NAFLD pathogenesis. DNA methylation signatures that can affect gene expression are influenced by environmental and lifestyle experiences such as diet, obesity, and physical activity and are reversible. Hence, DNA methylation signatures and modifiers in NAFLD may provide the basis for developing biomarkers indicating the onset and progression of NAFLD and therapeutics for NAFLD. Herein, we review an update on the recent findings in DNA methylation signatures and their roles in the pathogenesis of NAFLD and broaden people’s perspectives on potential DNA methylation-related treatments and biomarkers for NAFLD.
- Published
- 2020
- Full Text
- View/download PDF
183. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
- Author
-
Jin Ha Lee, Ji Young Oh, Soo Hyun Kim, In Jeong Oh, Yong-ho Lee, Keun Woo Lee, Woong Hee Lee, and Jeong-Hwan Kim
- Subjects
ginsenosides ,gypenoside LXXV ,drug discovery ,liver fibrosis ,nonalcoholic steatohepatitis (NASH) ,hepatic stellate cells ,Microbiology ,QR1-502 - Abstract
Ginsenosides have offered a wide array of beneficial roles in the pharmacological regulation of hepatic metabolic syndromes, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and obesity. Of the numerous ginsenosides, Rg3 has been widely investigated, but there have been few studies of gypenosides (Gyp). Particularly, no study on Gyp LXXV has been reported to date. Here, to firstly explore the pharmacological effects of Gyp LXXV against NASH and the related mechanism, methionine- and choline-deficient (MCD) diet-induced NASH mice and hepatic cells (stellate cells, hepatic macrophages, and hepatocytes) were selected. Gyp LXXV exhibited markedly alleviated MCD diet-induced hepatic injury, inflammation, and fibrosis by down-regulating hepatic fibrosis markers such as α-smooth muscle actin(α-SMA), collagen1, transforming growth factors-β (TGF-β1), tumor necrosis factor-α (TNF-α), MCP-1, interleukin (IL)-1β, nuclear factor κB (NFκB), and GRP78. Remarkably, histopathological studies confirmed that 15 mg/kg of Gyp LXXV administration to MCD diet-induced mice led to effective prevention of liver injury, lipid accumulation, and activation of hepatic macrophages, indicating that Gyp LXXV might be a potential anti-NASH drug.
- Published
- 2020
- Full Text
- View/download PDF
184. A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
- Author
-
Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, and Aysha Aslam
- Subjects
chronic hepatitis B ,nonalcoholic fatty liver disease (NAFLD) ,nonalcoholic steatohepatitis (NASH) ,serum biomarkers ,controlled attenuation parameter (CAP) ,transient elastography (Fibroscan) ,Biology (General) ,QH301-705.5 - Abstract
Hepatitis B virus (HBV) infection remains a global public problem despite the availability of an effective vaccine. In the past decades, nonalcoholic fatty liver disease (NAFLD) has surpassed HBV as the most common cause of chronic liver disease worldwide. The prevalence of concomitant chronic hepatitis B (CHB) and NAFLD thus reaches endemic proportions in geographic regions where both conditions are common. Patients with CHB and NAFLD are at increased risk of liver disease progression to cirrhosis and hepatocellular carcinoma. Due to the complexity of the pathogenesis, accurate diagnosis of NAFLD in CHB patients can be challenging. Liver biopsy is considered the gold standard for diagnosing and determining disease severity, but it is an invasive procedure with potential complications. There is a growing body of literature on the application of novel noninvasive serum biomarkers and advanced radiological modalities to diagnose and evaluate NAFLD, but most have not been adequately validated, especially for patients with CHB. Currently, there is no approved therapy for NAFLD, although many new agents are in different phases of development. This review provides a summary of the epidemiology, clinical features, diagnosis, and management of the NAFLD and highlights the unmet needs in the areas of CHB and NAFLD coexistence.
- Published
- 2020
- Full Text
- View/download PDF
185. Analytical performance of the Enhanced Liver Fibrosis (ELF) Test on the Atellica IM Analyzer.
- Author
-
Palladino, Agostino, Gee, Matthew, Shalhoub, Victoria, and Kiaei, David
- Subjects
- *
HEPATIC fibrosis , *MATRIX metalloproteinase inhibitors , *LIVER disease diagnosis , *TRABECULAR meshwork (Eye) , *NON-alcoholic fatty liver disease , *BIOMARKERS - Abstract
• ELFTM aids prognostic evaluation in patients with advanced liver fibrosis in NASH. • The ELF score comprises results of 3 fibrosis markers, HA, PIIINP, and TIMP-1. • The Atellica IM Analyzer was used for analytical performance of 3 analytes and ELF. • Detection capability, precision, interference, linearity, hook effect, were studied. • All predetermined requirements were met making the assay fit for clinical use. The Enhanced Liver Fibrosis (ELFTM) Test comprises 3 direct serum markers of fibrosis—hyaluronic acid (HA), amino-terminal pro-peptide of type III procollagen (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1)—whose results are combined in an algorithm to generate the ELF score. Outside the U.S., the ELF Test and score are CE marked for assessment of liver fibrosis severity in patients with signs, symptoms, or risk factors of chronic liver disease to support diagnosis of fibrosis staging or prognosis for likelihood of progression to cirrhosis and liver-related clinical events. In the U.S., the FDA granted de novo marketing authorization to aid prognostic evaluation of disease progression (to cirrhosis and liver-related clinical events) in nonalcoholic steatohepatitis patients with advanced liver fibrosis. We describe the analytical performance of the ELF analytes and score on the Atellica® IM Analyzer. Clinical and Laboratory Standards Institute protocols were followed for detection capability (limits of blank [LoB], detection [LoD], and quantitation [LoQ]), precision, interference, linearity, hook effect, and ELF reference interval. All parameters met predetermined requirements: HA (LoB 1.00 ng/mL, LoD 2.00 ng/mL, LoQ 3.00 ng/mL); PIIINP (LoB 0.50 ng/mL, LoD 0.75 ng/mL, LoQ 1.00 ng/mL); TIMP-1 (LoB 3.0 ng/mL, LoD 4.0 ng/mL, LoQ 5.0 ng/mL). Across the 3 assays, repeatability was ≤5.4% CV; within-lab precision was ≤8.5% CV. ELF score repeatability was ≤0.6% CV, within-lab precision ≤1.3% CV, and reproducibility ≤1.1% CV. Good correlation was obtained between the Atellica IM ELF and ADVIA Centaur ELF Tests (y = 1.01x − 0.22, r = 0.997). Assays were linear across analytical measuring ranges. Analytical performance validation results for the ELF Test and ELF score were excellent making the test acceptable for routine clinical use. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
186. Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease
- Author
-
Tea Lund Laursen, Anders Mellemkjær, Holger Jon Møller, Henning Grønbæk, and Konstantin Kazankov
- Subjects
Pharmacology ,Metabolic Syndrome ,obesity ,soluble CD163 ,Macrophages ,Clinical Biochemistry ,Fibrosis ,metabolic syndrome ,Liver ,Pharmaceutical Preparations ,Non-alcoholic Fatty Liver Disease ,nonalcoholic steatohepatitis (NASH) ,Drug Discovery ,Disease Progression ,Molecular Medicine ,Humans ,nonalcoholic fatty liver disease (NAFLD) - Abstract
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome and is rapidly emerging as the leading cause of liver-related morbidity and mortality. Macrophages play an essential role in the development and progression of NAFLD.AREAS COVERED: In this review, we provide an update on recent studies of drugs, which directly or indirectly affect macrophages in NAFLD, and discuss the implication of macrophage biomarkers to monitor the disease stage and progression/regression.EXPERT OPINION: There is an unmet need for better understanding of disease pathogenesis from hepatic fat accumulation to disease progression with inflammation and fibrosis. We expect that future research will uncover additional objects/pathways as treatment targets. We speculate that this will involve better characterization of the gut microbiome, damage-associated molecular patterns (DAMPS) or molecules and pathways involved in development of DAMPS, and advanced molecular biology studies including single-cell sequencing of macrophage subpopulations. In addition, we speculate that studies focusing on pharmaceuticals that improve insulin resistance, diminish the metabolic syndrome and reduce fibrosis will prevail.
- Published
- 2022
187. Involvement of the Autophagy-ER Stress Axis in High Fat/Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease
- Author
-
Xiu Zhou, Sherouk Fouda, Dongli Li, Kun Zhang, and Ji-Ming Ye
- Subjects
nonalcoholic fatty liver disease (NAFLD) ,nonalcoholic steatohepatitis (NASH) ,endoplasmic reticulum (ER) stress ,autophagy ,inflammation ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease that can progress from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), and even further to liver cirrhosis or liver cancer. Overconsumption of high fat and/or carbohydrate are among the most common lifestyle factors that drive the development and progression of NAFLD. This review evaluates recent reports on the involvement of autophagy and endoplasmic reticulum (ER) stress in the pathogenesis of NAFLD. Here, we reveal a mechanism of an intrinsically linked axis of impaired autophagy and unresolved ER stress that mediates the development and progression of NAFLD resulting from the overconsumption of high fat and/or carbohydrate.
- Published
- 2020
- Full Text
- View/download PDF
188. Intracellular Toxic Advanced Glycation End-Products Promote the Production of Reactive Oxygen Species in HepG2 Cells
- Author
-
Akiko Sakasai-Sakai, Takanobu Takata, and Masayoshi Takeuchi
- Subjects
nonalcoholic fatty liver disease (NAFLD) ,nonalcoholic steatohepatitis (NASH) ,advanced glycation end-products (AGEs) ,glyceraldehyde (GA) ,glyceraldehyde-derived AGEs ,toxic AGEs (TAGE) ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Hepatocyte cell death is a key process in the pathogenesis of nonalcoholic steatohepatitis (NASH). However, the factors responsible for and mechanisms underlying NASH-related cell death have not yet been elucidated in detail. We herein investigated the effects of intracellular glyceraldehyde (GA)-derived advanced glycation end-products (AGEs), named toxic AGEs (TAGE), on the production of reactive oxygen species (ROS), which have been implicated in the pathogenesis of NASH. Cell death related to intracellular TAGE accumulation was eliminated in the hepatocyte carcinoma cell line HepG2 by the antioxidant effects of N-acetyl-L-cysteine. The intracellular accumulation of TAGE increased ROS production and the expression of Nrf2, including its downstream gene. These results suggest that ROS are produced in association with the accumulation of TAGE and are a direct trigger for cell death. We also investigated the factors responsible for these increases in ROS. Catalase activity did not decrease with the accumulation of TAGE, while mitochondrial membrane depolarization was enhanced in cells treated with GA. These results indicate that TAGE play an important role in mitochondrial abnormalities and increases in ROS production, both of which are characteristic features of NASH. The suppression of TAGE accumulation has potential as a new therapeutic target in the progression of NASH.
- Published
- 2020
- Full Text
- View/download PDF
189. Lemon Balm and Its Constituent, Rosmarinic Acid, Alleviate Liver Damage in an Animal Model of Nonalcoholic Steatohepatitis
- Author
-
Myungsuk Kim, GyHye Yoo, Ahmad Randy, Yang-Ju Son, Chi Rac Hong, Sang Min Kim, and Chu Won Nho
- Subjects
nonalcoholic steatohepatitis (NASH) ,lemon balm extract (LBE) ,rosmarinic acid (RA) ,AMP-activated protein kinase (AMPK) ,antioxidants ,anti-inflammation ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Nonalcoholic fatty liver disease (NAFLD) ranges in severity from hepatic steatosis to cirrhosis. Lemon balm and its major constituent, rosmarinic acid (RA), effectively improve the liver injury and obesity; however, their therapeutic effects on nonalcoholic steatohepatitis (NASH) are unknown. In this study, we investigated the effects of RA and a lemon balm extract (LBE) on NAFLD and liver fibrosis and elucidated their mechanisms. Palmitic acid (PA)-exposed HepG2 cells and db/db mice fed a methionine- and choline-deficient (MCD) diet were utilized to exhibit symptoms of human NASH. LBE and RA treatments alleviated the oxidative stress by increasing antioxidant enzymes and modulated lipid metabolism-related gene expression by the activation of adenosine monophosphate-activated protein kinase (AMPK) in vitro and in vivo. LBE and RA treatments inhibited the expression of genes involved in hepatic fibrosis and inflammation in vitro and in vivo. Together, LBE and RA could improve liver damage by non-alcoholic lipid accumulation and may be promising medications to treat NASH.
- Published
- 2020
- Full Text
- View/download PDF
190. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan
- Author
-
Ming-Chao Tsai, Yu-Yin Liu, Chih-Che Lin, Chih-Chi Wang, Yi-Ju Wu, Chee-Chien Yong, Kuang-Den Chen, Seng-Kee Chuah, Chih-Chien Yao, Pao-Yuan Huang, Chien-Hung Chen, Tsung-Hui Hu, and Chao-Long Chen
- Subjects
gut microbiota ,nonalcoholic fatty liver disease (nafld) ,nonalcoholic fatty liver (nafl) ,nonalcoholic steatohepatitis (nash) ,ruminococcus ,Nutrition. Foods and food supply ,TX341-641 - Abstract
The gut microbiota plays a role in nonalcoholic fatty liver disease (NAFLD), but data about gut dysbiosis in Asians with NAFLD remains scarce. We analyzed the differences in fecal microbiota between adults with and without NAFLD. This cross-sectional study examined adults with histology-proven NAFLD (25 nonalcoholic fatty liver (NAFL) patients, 25 nonalcoholic steatohepatitis (NASH) patients, and 25 living liver donors (healthy controls)). The taxonomic composition of the gut microbiota was determined by 16S ribosomal RNA gene sequencing of stool samples. The NAFL and NASH groups showed lower total bacterial diversity and richness than the controls. NAFLD patients had higher levels of the phylum Bacteroidetes and lower levels of Firmicutes than controls. The genus Ruminococcaceae UCG-010, family Ruminococcaceae, order Clostridiales, and class Clostridia were less abundant in patients with NAFL or NASH than healthy individuals. The lipopolysaccharide biosynthesis pathway was differentially enriched in the NASH group. This study examined the largest number of Asian patients with biopsy-proven NAFL and NASH in terms of dysbiosis of the gut microbiota in NAFLD patients. NAFLD patients had higher levels of Bacteroidetes and lower levels of Firmicutes. These results are different from research from western countries and could provide different targets for therapies by region.
- Published
- 2020
- Full Text
- View/download PDF
191. Metabolic Syndrome and Related Liver Diseases
- Author
-
Delgado-Borrego, Aymin, Lipshultz, Steven E., editor, Messiah, Sarah E., editor, and Miller, Tracie L., editor
- Published
- 2012
- Full Text
- View/download PDF
192. Sphingomyelin synthase-related protein SMSr is a phosphatidylethanolamine phospholipase C that promotes nonalcoholic fatty liver disease.
- Author
-
Chiang YP, Li Z, He M, Jones Q, Pan M, Han X, and Jiang XC
- Subjects
- Animals, Humans, Mice, Fructose adverse effects, Glucosylceramides metabolism, Liver metabolism, Liver Cirrhosis pathology, Phosphatidylethanolamines blood, Mice, Knockout, Male, Female, Diet, High-Fat adverse effects, Neoplasms genetics, Neoplasms metabolism, Non-alcoholic Fatty Liver Disease genetics, Non-alcoholic Fatty Liver Disease metabolism, Transferases (Other Substituted Phosphate Groups) genetics, Transferases (Other Substituted Phosphate Groups) metabolism
- Abstract
Sphingomyelin synthase (SMS)-related protein (SMSr) is a phosphatidylethanolamine phospholipase C (PE-PLC) that is conserved and ubiquitous in mammals. However, its biological function is still not clear. We previously observed that SMS1 deficiency-mediated glucosylceramide accumulation caused nonalcoholic fatty liver diseases (NAFLD), including nonalcoholic steatohepatitis (NASH) and liver fibrosis. Here, first, we evaluated high-fat diet/fructose-induced NAFLD in Smsr KO and WT mice. Second, we evaluated whether SMSr deficiency can reverse SMS1 deficiency-mediated NAFLD, using Sms1/Sms2 double and Sms1/Sms2/Smsr triple KO mice. We found that SMSr/PE-PLC deficiency attenuated high-fat diet/fructose-induced fatty liver and NASH, and attenuated glucosylceramide accumulation-induced NASH, fibrosis, and tumor formation. Further, we found that SMSr/PE-PLC deficiency reduced the expression of many inflammatory cytokines and fibrosis-related factors, and PE supplementation in vitro or in vivo mimicked the condition of SMSr/PE-PLC deficiency. Furthermore, we demonstrated that SMSr/PE-PLC deficiency or PE supplementation effectively prevented membrane-bound β-catenin transfer to the nucleus, thereby preventing tumor-related gene expression. Finally, we observed that patients with NASH had higher SMSr protein levels in the liver, lower plasma PE levels, and lower plasma PE/phosphatidylcholine ratios, and that human plasma PE levels are negatively associated with tumor necrosis factor-α and transforming growth factor β1 levels. In conclusion, SMSr/PE-PLC deficiency causes PE accumulation, which can attenuate fatty liver, NASH, and fibrosis. These results suggest that SMSr/PE-PLC inhibition therapy may mitigate NAFLD., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
193. Heterozygous midnolin knockout attenuates severity of nonalcoholic fatty liver disease in mice fed a Western-style diet high in fat, cholesterol, and fructose.
- Author
-
Kweon SM, Irimia-Dominguez J, Kim G, Fueger PT, Asahina K, Lai KK, Allende DS, Lai QR, Lou CH, Tsark WM, Yang JD, Ng DS, Lee JS, Tso P, Huang W, and Lai KKY
- Subjects
- Mice, Animals, Fructose metabolism, Diet, High-Fat methods, Liver metabolism, Cholesterol metabolism, Mice, Knockout, Disease Models, Animal, Mice, Inbred C57BL, Non-alcoholic Fatty Liver Disease genetics, Non-alcoholic Fatty Liver Disease metabolism
- Abstract
Although midnolin has been studied for over 20 years, its biological roles in vivo remain largely unknown, especially due to the lack of a functional animal model. Indeed, given our recent discovery that the knockdown of midnolin suppresses liver cancer cell tumorigenicity and that this antitumorigenic effect is associated with modulation of lipid metabolism, we hypothesized that knockout of midnolin in vivo could potentially protect from nonalcoholic fatty liver disease (NAFLD) which has become the most common cause of chronic liver disease in the Western world. Accordingly, in the present study, we have developed and now report on the first functional global midnolin knockout mouse model. Although the overwhelming majority of global homozygous midnolin knockout mice demonstrated embryonic lethality, heterozygous knockout mice were observed to be similar to wild-type mice in their viability and were used to determine the effect of reduced midnolin expression on NAFLD. We found that global heterozygous midnolin knockout attenuated the severity of NAFLD in mice fed a Western-style diet, high in fat, cholesterol, and fructose, and this attenuation in disease was associated with significantly reduced levels of large lipid droplets, hepatic free cholesterol, and serum LDL, with significantly differential gene expression involved in cholesterol/lipid metabolism. Collectively, our results support a role for midnolin in regulating cholesterol/lipid metabolism in the liver. Thus, midnolin may represent a novel therapeutic target for NAFLD. Finally, our observation that midnolin was essential for survival underscores the broad importance of this gene beyond its role in liver biology. NEW & NOTEWORTHY We have developed and now report on the first functional global midnolin knockout mouse model. We found that global heterozygous midnolin knockout attenuated the severity of nonalcoholic fatty liver disease (NAFLD) in mice fed a Western-style diet, high in fat, cholesterol, and fructose, and this attenuation in disease was associated with significantly reduced levels of large lipid droplets, hepatic free cholesterol, and serum LDL, with significantly differential gene expression involved in cholesterol/lipid metabolism.
- Published
- 2023
- Full Text
- View/download PDF
194. Hepatic venous pressure gradient and rebleeding risk of patients with nonalcoholic steatohepatitis cirrhosis after variceal bleeding.
- Author
-
Shi Y, Shen W, Xu G, Wang X, and Ning B
- Abstract
Background and Aims: Hepatic venous pressure gradient (HVPG) has a strong predictive value for variceal rebleeding in cirrhotic patients, but the accuracy of HVPG may be compromised in nonalcoholic steatohepatitis (NASH) cirrhosis. This study aimed to evaluate the accuracy of HVPG and portal pressure gradient (PPG) for predicting rebleeding in NASH cirrhosis after acute variceal bleeding., Patients and Methods: Thirty-eight NASH cirrhosis patients and 82 hepatitis B virus (HBV) cirrhosis patients with acute variceal bleeding were included in this study. All patients recived transjugular intrahepatic portalsystemic shunt (TIPS). The prognostic value of HVPG and PPG for variceal rebleeding was evaluated., Results: Compared with HBV cirrhosis, NASH cirrhosis demonstrated a lower HVPG (15.3 ± 3.8 vs. 18.0 ± 4.8; p = 0.003) and lower PPG (18.0 ± 3.7 vs. 20.0 ± 3.4; p = 0.005). HVPG (AUC = 0.82; p = 0.002) and PPG (AUC = 0.72; p = 0.027) had promising prognostic value among NASH cirrhosis patients. The optimal threshold of HVPG and PPG for predicting rebleeding in NASH cirrhosis was 17 mmHg and 20 mmHg. At multivariate analysis, HVPG ≥17 mmHg was a significant predictor of variceal rebleeding (HR 9.40; 95% CI 1.85-47.70; p = 0.007)., Conclusion: In the patients with cirrhosis and vairceal bleeding, the levels of HVPG and PPG were found to be low in NASH cirrhosis than HBV cirrhosis. However, the prevalence of rebleeding was similar between two groups. HVPG measurement is still an accurate way to assess the risk of variceal rebleeding in NASH cirrhosis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Shi, Shen, Xu, Wang and Ning.)
- Published
- 2023
- Full Text
- View/download PDF
195. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk.
- Author
-
Nysather J, Kaya E, Manka P, Gudsoorkar P, and Syn WK
- Subjects
- United States, Humans, Cardiometabolic Risk Factors, Cell Physiological Phenomena, Non-alcoholic Fatty Liver Disease diagnosis, Renal Insufficiency, Chronic epidemiology
- Abstract
Nonalcoholic fatty liver disease is a multisystem condition with effects beyond the liver. The identification of chronic kidney disease as an independent mediator of nonalcoholic fatty liver disease or associated entity with shared cardiometabolic risk factors remains controversial and continues to draw scientific interest. With increasing prevalence of nonalcoholic fatty liver disease and lack of Food and Drug Administration approved therapies, these shared cardiometabolic risk factors have drawn significant attention. In this article, we review shared pathophysiological mechanisms between nonalcoholic fatty liver disease and chronic kidney disease along with current treatment strategies that might be useful for both disease processes., (Copyright © 2023 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
196. PEG-GNPs aggravate MCD-induced steatohepatitic injury and liver fibrosis in mice through excessive lipid accumulation-mediated hepatic inflammatory damage.
- Author
-
Chen H, Zhou S, Chen W, Zhu M, Yu H, Zheng L, Wang B, Wang M, and Feng W
- Subjects
- Mice, Animals, Gold, Liver Cirrhosis complications, Triglycerides metabolism, Non-alcoholic Fatty Liver Disease etiology, Metal Nanoparticles
- Abstract
Rapid development of gold nanoparticles (GNPs) in delivering pharmaceutics and therapeutics approaches still linger the concerns of their toxic effects. Nonalcoholic steatohepatitis (NASH) is characterized by excessive lipid accumulation and overt hepatic inflammatory damage, and is the leading cause of chronic liver disease worldwide. This study aimed to assess the potential hepatic effects of GNPs on NASH phenotype and progression in mice. Mice were fed a MCD diet for 8 weeks to elicit NASH and then intravenously injected with PEG-GNPs at a single dose of 1, 5, and 25 mg/kg-bw. After 24 h and 1 week of administration, the levels of plasma ALT and AST, and the number of lipid droplets, the degree of lobular inflammation and the contents of triglycerides and cholesterols in the livers of the NASH mice significantly increased compared with the untreated NASH mice, indicating that the severity of MCD diet-induced NASH-like symptoms in mice increased after PEG-GNP administration. Moreover, the aggravated hepatic steatosis in a manner involving altered expression of the genes related to hepatic de novo lipogenesis, lipolysis, and fatty acid oxidation was observed after PEG-GNP administration. Additionally, the RNA levels of biomarkers of hepatic pro-inflammatory responses, endoplasmic reticulum stress, apoptosis, and autophagy in MCD-fed mice increased compared with the untreated NASH group. Moreover, PEG-GNP-treated NASH mice displayed an increase in MCD diet-induced hepatic fibrosis, revealed by massive deposition of collagen fiber in the liver and increased expression of fibrogenic genes. Collectively, these results suggest that hepatic GNP deposition after PEG-GNP administration increase the severity of MCD-induced NASH phenotype in mice, which is attributable to, in large part, increased steatohepatitic injury and liver fibrosis in mice., Competing Interests: Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
197. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD).
- Author
-
Hanson, Amanda, Wilhelmsen, Danielle, and DiStefano, Johanna K.
- Subjects
- *
FIBROSIS , *NON-coding RNA , *FATTY degeneration , *MORTALITY , *DISEASE progression , *DEVELOPMENTAL biology - Abstract
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions ranging from hepatic steatosis to inflammation (nonalcoholic steatohepatitis or NASH) with or without fibrosis, in the absence of significant alcohol consumption. The presence of fibrosis in NASH patients is associated with greater liver-related morbidity and mortality; however, the molecular mechanisms underlying the development of fibrosis and cirrhosis in NAFLD patients remain poorly understood. Long non-coding RNAs (lncRNAs) are emerging as key contributors to biological processes that are underpinning the initiation and progression of NAFLD fibrosis. This review summarizes the experimental findings that have been obtained to date in animal models of liver fibrosis and NAFLD patients with fibrosis. We also discuss the potential applicability of circulating lncRNAs to serve as biomarkers for the diagnosis and prognosis of NAFLD fibrosis. A better understanding of the role played by lncRNAs in NAFLD fibrosis is critical for the identification of novel therapeutic targets for drug development and improved, noninvasive methods for disease diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
198. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
- Author
-
Kim, Nathan G., Nguyen, Pauline P., Dang, Hansen, Kumari, Radhika, Garcia, Gabriel, Esquivel, Carlos O., and Nguyen, Mindie H.
- Subjects
- *
LIVER cancer , *CANCER patients , *HEPATITIS C , *HEPATITIS B , *UNIVERSITY hospitals - Abstract
Background: Hepatocellular carcinoma (HCC) is one of the few cancers whose incidence continues to increase. The goal of the current study was to investigate the presentation and survival trends of patients with HCC presenting to a university hospital between 1998 and 2015.Methods: Study data were ascertained by individual chart review with survival data also supplemented by National Death Index query up to December 31, 2015. Patients were divided into three 6-year groups by diagnosis date (1998-2003, 2004-2009, and 2010-2015).Results: A total of 2106 consecutive patients with HCC were included. The majority of patients had either hepatitis C (56.7%) or hepatitis B (22.1%), but cases of nonalcoholic steatohepatitis HCC increased by 68% over the most recent time period. Screening/surveillance identified 61% of HCC cases, but only 31% of these patients underwent curative treatment, which did not increase significantly over time. The overall median survival was 29.8 months (2.48 years) and without improvement over time. On multivariable analysis, Asian or Hispanic ethnicity, meeting Milan criteria, and receiving any of the standard HCC treatments were found to be significantly associated with improved survival, but diagnosis time period and liver disease etiology were not.Conclusions: Over the last 18 years, the percentage of cases of nonalcoholic steatohepatitis HCC has increased but not overall survival. It is interesting to note that only 31% of patients with HCC identified via screening/surveillance received any curative treatment. Further research is needed to better understand the barriers to curative care for patients with HCC and the causes of the lack of improvement in survival in the more recent patient cohort. Cancer 2018;124:2588-98. © 2018 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
199. High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease.
- Author
-
Tepper, Clifford G., Dang, Julie H. T., Stewart, Susan L., Fang, Dao M., Wong, Kimberly A., Liu, Stephenie Y., Davis, Ryan R., Dao, Doan Y., Gregg, Jeffrey P., Török, Natalie J., Chen, Jr., Moon S., and Chen, Moon S Jr.
- Subjects
- *
LIVER diseases , *PHOSPHOLIPASES , *FATTY liver , *SINGLE nucleotide polymorphisms , *GENERALIZABILITY theory , *PATIENTS - Abstract
Background: An exploratory study was performed to determine the prevalence of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs78409 [G] allele among the Hmong as a risk factor for nonalcoholic fatty liver disease (NAFLD). NAFLD/nonalcoholic steatohepatitis is the world's most common chronic liver disease and is expected to replace viral hepatitis as the leading cause of cirrhosis and potential precursor to hepatocellular carcinoma (HCC). Of all populations in California, the Hmong experience the highest risk of death from HCC and the highest prevalence of metabolic syndrome risk factors among Asians that predispose them to NAFLD. Here a genetic explanation was sought for the high rates of chronic liver disease among the Hmong. The literature pointed to the PNPLA3 rs738409 [G] allele as a potential genetic culprit.Methods: Cell-free DNA was isolated from 26 serum samples previously collected in community settings. Quantitative polymerase chain reaction-based single-nucleotide polymorphism (SNP) genotyping was performed with a validated TaqMan SNP genotyping assay, and results were analyzed with TaqMan Genotyper software.Results: The PNPLA3 rs738409 [C>G] variant occurred at a frequency of 0.46 (12 of 26; 95% confidence interval, 0.27-0.67). This carrier rate would rank the Hmong as the third highest population in the 1000 Genomes Project.Conclusions: Although this small sample size limits the generalizability, the high frequency rates of this allele along with the presence of metabolic syndrome risk factors warrant further studies into the etiology of NAFLD among the Hmong. Cancer 2018;124:1583-9. © 2018 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
200. The Effects of Physical Exercise on Fatty Liver Disease.
- Author
-
van der Windt, Dirk J., Sud, Vikas, Hongji Zhang, Tsung, Allan, and Hai Huang
- Subjects
FATTY liver ,PHYSICAL activity ,EXERCISE physiology ,HEALTH behavior ,THERAPEUTICS - Abstract
The increasing prevalence of obesity has made nonalcoholic fatty liver disease (NAFLD) the most common chronic liver disease. As a consequence, NAFLD and especially its inflammatory form nonalcoholic steatohepatitis (NASH) are the fastest increasing etiology of end-stage liver disease and hepatocellular carcinoma. Physical inactivity is related to the severity of fatty liver disease irrespective of body weight, supporting the hypothesis that increasing physical activity through exercise can improve fatty liver disease. This review summarizes the evidence for the effects of physical exercise on NAFLD and NASH. Several clinical trials have shown that both aerobic and resistance exercise reduce the hepatic fat content. From clinical and basic scientific studies, it is evident that exercise affects fatty liver disease through various pathways. Improved peripheral insulin resistance reduces the excess delivery of free fatty acids and glucose for free fatty acid synthesis to the liver. In the liver, exercise increases fatty acid oxidation, decreases fatty acid synthesis, and prevents mitochondrial and hepatocellular damage through a reduction of the release of damage-associated molecular patterns. In conclusion, physical exercise is a proven therapeutic strategy to improve fatty liver disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.